Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quinn, J. E.
Right arrow Articles by Harkin, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quinn, J. E.
Right arrow Articles by Harkin, D. P.
[Cancer Research 63, 6221-6228, October 1, 2003]
© 2003 American Association for Cancer Research

Regular Articles

BRCA1 Functions as a Differential Modulator of Chemotherapy-induced Apoptosis1

Jennifer E. Quinn2, Richard D. Kennedy2, Paul B. Mullan, Paula M. Gilmore, Michael Carty, Patrick G. Johnston and D. Paul Harkin3

Department of Oncology, Cancer Research Centre, Queen’s University Belfast, Belfast, Northern Ireland BT9 7AB, United Kingdom

We have evaluated the role played by BRCA1 in mediating the phenotypic response to a range of chemotherapeutic agents commonly used in cancer treatment. Here we provide evidence that BRCA1 functions as a differential mediator of chemotherapy-induced apoptosis. Specifically, we demonstrate that BRCA1 mediates sensitivity to apoptosis induced by antimicrotubule agents but conversely induces resistance to DNA-damaging agents. These data are supported by a variety of experimental models including cells with inducible expression of BRCA1, siRNA-mediated inactivation of endogenous BRCA1, and reconstitution of BRCA1-deficient cells with wild-type BRCA1. Most notably we demonstrate that BRCA1 induces a 10–1000-fold increase in resistance to a range of DNA-damaging agents, in particular those that give rise to double-strand breaks such as etoposide or bleomycin. In contrast, BRCA1 induces a >1000-fold increase in sensitivity to the spindle poisons, paclitaxel and vinorelbine. Fluorescence-activated cell sorter analysis demonstrated that BRCA1 mediates G2/M arrest in response to both antimicrotubule and DNA-damaging agents. However, poly(ADP-ribose) polymerase and caspase-3 cleavage assays indicate that the differential effect mediated by BRCA1 in response to these agents occurs through the inhibition or induction of apoptosis. Therefore, our data suggest that BRCA1 acts as a differential modulator of apoptosis depending on the nature of the cellular insult.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Swanton, B. Nicke, M. Schuett, A. C. Eklund, C. Ng, Q. Li, T. Hardcastle, A. Lee, R. Roy, P. East, et al.
Chromosomal instability determines taxane response
PNAS, May 26, 2009; 106(21): 8671 - 8676.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Santarosa, L. Del Col, E. Tonin, A. Caragnano, A. Viel, and R. Maestro
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Mol. Cancer Ther., April 1, 2009; 8(4): 844 - 854.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo
Advances in Breast Cancer: Pathways to Personalized Medicine
Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Zajac, M. V. Moneo, A. Carnero, J. Benitez, and B. Martinez-Delgado
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
Mol. Cancer Ther., August 1, 2008; 7(8): 2358 - 2366.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden
Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway
J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. P. Martin, T. C. Hamilton, and R. J. Schilder
Platinum Resistance: The Role of DNA Repair Pathways
Clin. Cancer Res., March 1, 2008; 14(5): 1291 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
G. Bepler
Genes Predictive of Chemotherapeutic Efficacy in Non-small Cell Lung Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 350 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. Quinn, C. R. James, G. E. Stewart, J. M. Mulligan, P. White, G. K.F. Chang, P. B. Mullan, P. G. Johnston, R. H. Wilson, and D. P. Harkin
BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy
Clin. Cancer Res., December 15, 2007; 13(24): 7413 - 7420.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
B. A. Olofsson, C. M. Kelly, J. Kim, S. M. Hornsby, and J. Azizkhan-Clifford
Phosphorylation of Sp1 in Response to DNA Damage by Ataxia Telangiectasia-Mutated Kinase
Mol. Cancer Res., December 1, 2007; 5(12): 1319 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Lin and J. H. Wilson
Transcription-Induced CAG Repeat Contraction in Human Cells Is Mediated in Part by Transcription-Coupled Nucleotide Excision Repair
Mol. Cell. Biol., September 1, 2007; 27(17): 6209 - 6217.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Bullinger, F. G. Rucker, S. Kurz, J. Du, C. Scholl, S. Sander, A. Corbacioglu, C. Lottaz, J. Krauter, S. Frohling, et al.
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia
Blood, August 15, 2007; 110(4): 1291 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. D. Treszezamsky, L. A. Kachnic, Z. Feng, J. Zhang, C. Tokadjian, and S. N. Powell
BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II
Cancer Res., August 1, 2007; 67(15): 7078 - 7081.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. M.R. Bhat and V. Setaluri
Microtubule-Associated Proteins as Targets in Cancer Chemotherapy
Clin. Cancer Res., May 15, 2007; 13(10): 2849 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Bellmunt, L Paz-Ares, M Cuello, F. Cecere, S Albiol, V Guillem, E Gallardo, J Carles, P Mendez, J. de la Cruz, et al.
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
Ann. Onc., March 1, 2007; 18(3): 522 - 528.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin
BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
Oncologist, February 1, 2007; 12(2): 142 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
C. DelloRusso, P. L. Welcsh, W. Wang, R. L. Garcia, M.-C. King, and E. M. Swisher
Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation
Mol. Cancer Res., January 1, 2007; 5(1): 35 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. I. Yarden and M. Z. Papa
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions.
Mol. Cancer Ther., June 1, 2006; 5(6): 1396 - 1404.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. de las Penas, M. Sanchez-Ronco, V. Alberola, M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, et al.
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
Ann. Onc., April 1, 2006; 17(4): 668 - 675.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Ramirez, R. Rosell, M. Taron, M. Sanchez-Ronco, V. Alberola, R. de las Penas, J. M. Sanchez, T. Moran, C. Camps, B. Massuti, et al.
14-3-3{sigma} Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non-Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group
J. Clin. Oncol., December 20, 2005; 23(36): 9105 - 9112.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
R. D. Kennedy and A. D. D'Andrea
The Fanconi Anemia/BRCA pathway: new faces in the crowd
Genes & Dev., December 15, 2005; 19(24): 2925 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. A. Martin and T. Ouchi
BRCA1 Phosphorylation Regulates Caspase-3 Activation in UV-Induced Apoptosis
Cancer Res., December 1, 2005; 65(23): 10657 - 10662.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. D. Kennedy, J. J. Gorski, J. E. Quinn, G. E. Stewart, C. R. James, S. Moore, K. Mulligan, E. D. Emberley, T. F. Lioe, P. J. Morrison, et al.
BRCA1 and c-Myc Associate to Transcriptionally Repress Psoriasin, a DNA Damage-Inducible Gene
Cancer Res., November 15, 2005; 65(22): 10265 - 10272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung
Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells
Cancer Res., May 1, 2005; 65(9): 3671 - 3681.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients
Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A.-M. Simeone, C.-X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
Carcinogenesis, May 1, 2005; 26(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Narod and K. Offit
Prevention and Management of Hereditary Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. D. Kennedy, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin
The Role of BRCA1 in the Cellular Response to Chemotherapy
J Natl Cancer Inst, November 17, 2004; 96(22): 1659 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al.
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. M. Gilmore, N. McCabe, J. E. Quinn, R. D. Kennedy, J. J. Gorski, H. N. Andrews, S. McWilliams, M. Carty, P. B. Mullan, W. P. Duprex, et al.
BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3
Cancer Res., June 15, 2004; 64(12): 4148 - 4154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.